Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes

Haemophilia - Tập 14 Số 3 - Trang 476-483 - 2008
Rivka Yatuv1, I. DAYAN1, Lea Carmel-Goren1, Micah Robinson1, Irit Aviv1, Mirela Goldenberg-Furmanov1, Moshe Baru1
1Omri Laboratories Ltd, Rehovot, Israel

Tóm tắt

Summary.  Recombinant activated factor VII (rFVIIa) is an effective treatment of the haemophilia patient with inhibitors and acquired haemophilia. However, on account of its relatively short half‐life (HL), achieving therapeutic efficacy with FVIIa requires repeated injections. The development of a long‐acting FVIIa product would therefore be beneficial. The formulation of factor VIII with PEGylated liposomes (PEGLip) was previously shown to extend the bleeding‐free period in haemophilia patients. We report here an enhancement of haemostatic efficacy by similarly formulating FVIIa with PEGLip. Surface plasmon resonance analysis indicated that FVIIa binds non‐covalently but with high affinity and specificity to PEGLip. A one‐stage clotting assay demonstrated that formulation of FVIIa with PEGLip does not affect FVIIa activity and stability. A pharmacokinetic study in rats demonstrated that PEGLip formulation of FVIIa extends circulation time and results in higher FVIIa levels several hours after injection. Thromboelastography experiments indicated that PEGLip‐FVIIa induces faster clot formation and higher clot stability than standard formulated FVIIa. These results suggest that formulation of FVIIa with PEGLip may lead to a safe and effective long‐acting FVIIa that improves the care of haemophilic patients with inhibitors and acquired haemophilia.

Từ khóa


Tài liệu tham khảo

10.1016/S0140-6736(88)90259-0

10.1046/j.1365-2516.1998.00209.x

10.1055/s-2000-8463

10.1055/s-0037-1615357

10.1053/shem.2001.29507

10.1053/j.seminhematol.2003.11.008

10.1038/clpt.1994.80

10.1097/01.mbc.0000169218.15926.34

Ingerslev J, 1998, Home treatment with recombinant activated factor VII: results from one centre, Blood Coagul Fibrinol, 9, S107

10.1055/s-0037-1615388

10.1046/j.1538-7836.2003.00059.x

10.1053/j.seminhematol.2003.11.002

10.1111/j.1365-2516.2005.01075.x

10.1046/j.1365-2516.1999.00032.x

10.1182/blood-2003-05-1369

10.1161/01.ATV.0000257204.82396.2b

10.1111/j.1365-2141.2007.06534.x

10.1111/j.1365-2516.2007.01524.x

Sorensen BB, 2007, Effect fo glycopegylation™ on the pharmacokineticproperties of FVIIa, J Thromb Haemost, 5, P‐T‐012

Bayer RJ, 2007, Development of long‐acting FVIIa derivatives by glycopegylationTM, J Thromb Haemost, 5, P‐T‐016

Baru M, 2005, Factor VIII efficient and specific non‐covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy, Thromb Haemost, 93, 1061, 10.1160/TH04-08-0485

10.1182/blood-2006-03-008276

10.1111/j.1365-2516.2007.01502.x

Jönsson U, 1991, Real‐time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology, BioTechniques, 11, 620

10.1097/00001721-200004001-00006

10.1111/j.1538-7836.2004.00528.x

10.1055/s-2006-939557

10.1046/j.1538-7836.2003.00075.x

10.1111/j.1365-2141.2005.05820.x

Thomsen MK, 1993, Pharmacokinetics of recombinant factor VIIa in the rat – a comparison of bio‐, immuno‐ and isotope assays, Thromb Haemost, 70, 458, 10.1055/s-0038-1649605

10.1111/j.1365-2141.1984.tb06121.x

10.1016/0049-3848(94)90227-5

10.1046/j.1538-7836.2003.00242.x

10.1053/j.seminhematol.2005.11.025

Thông tin
Thông tin xuất bản

Haemophilia

Tập 14 Số 3

476-483

Thông tin tác giả